Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.
about
Bevacizumab and daily temozolomide for recurrent glioblastoma."One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade gliomaThe efficacy of temozolomide for recurrent glioblastoma multiforme.Dose-dense temozolomide: is it still promising?Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patientsBevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma.The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.t-AUCB, an improved sEH inhibitor, suppresses human glioblastoma cell growth by activating NF-κB-p65.Management and treatment recommendations for World Health Organization Grade III and IV gliomas.Indications and Efficacy of Gamma Knife Stereotactic Radiosurgery for Recurrent Glioblastoma: 2 Decades of Institutional Experience.Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic compaWilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
P2860
Q33396384-E8FF2EBC-786E-415E-A74C-2F16506DB913Q33405170-557F1A63-9B15-473A-B9F4-6085E184D878Q34062033-499410C4-8460-4E20-B119-618C6F3476A6Q34297519-F6002163-DA63-4AC2-A60C-621797F571C8Q35943654-9E94ADD1-6078-4006-B325-FA1A75EC00FDQ36544101-A67DBEDF-8347-435B-9F01-AF5D856F4841Q37696867-494268D8-6508-46E8-B809-7A5D90DEF42EQ38068203-B4DFDCCC-1177-478B-9638-A80F9FDB39A9Q38179019-A6A3AE46-BA2C-4862-B248-47085B2AC580Q38205133-36CFB969-A57D-4E31-852E-65E331A6BC57Q38720644-0FDC13BB-516A-455E-BB9E-003109B23576Q39387287-55360687-0BD1-490E-A9EF-B6AA4F369940Q41706326-C7D3F616-CCAC-45CC-B605-17FF169B7F89Q46231452-C343E94F-5DD6-41F8-AC55-A1CD62FC14D2Q47145292-12B9EFEA-74EE-4945-8587-C1C65F1A282AQ48280437-E892FB4C-2D01-448E-8DFE-E85E3827604B
P2860
Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Efficacy of protracted dose-de ...... h recurrent high-grade glioma.
@ast
Efficacy of protracted dose-de ...... h recurrent high-grade glioma.
@en
type
label
Efficacy of protracted dose-de ...... h recurrent high-grade glioma.
@ast
Efficacy of protracted dose-de ...... h recurrent high-grade glioma.
@en
prefLabel
Efficacy of protracted dose-de ...... h recurrent high-grade glioma.
@ast
Efficacy of protracted dose-de ...... h recurrent high-grade glioma.
@en
P2093
P2860
P1476
Efficacy of protracted dose-de ...... h recurrent high-grade glioma.
@en
P2093
Beste M Atasoy
Hale B Caglar
Meric Sengoz
Zuleyha Akgun
P2860
P2888
P304
P356
10.1007/S11060-010-0423-2
P577
2010-09-29T00:00:00Z
P5875
P6179
1049942795